PRS33 Economic Burden in Direct Costs of Chronic Obstructive Pulmonary Disease (COPD) in Russia  by Krysanova, V. & Krysanov, I.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A593
for moderate-risk RR2378 ($75) for all ages. Average reimbursement rate was RR2,000 
($63) per outpatient episode. The average cost of hospitalization was RR20,870 ($655/
n= 500), RR20,925 ($657/n= 125) for low-risk, RR20,947 ($657/n= 364) for moderate-
risk, and RR17,684 ($554/n= 11) for high-risk patients; with 60%-80% of patients 
with CAP hospitalized and the estimated number of CAP patients of age 50 and 
older in Tver 3,249, the annual cost of CAP to payer is RR53,448,423 (~$1.7million); 
the national estimates of cost of CAP in senior adults was $124million. Employed 
patients comprise 12.8% and 18.3% among the inpatient and outpatient cases, 
respectively, and days lost from work per employed patient was 8.0 (inpatient) and 
7.0 (outpatient). ConClusions: CAP in adults is a significant cause of resource use 
and health care cost in Russia, inpatient care constitutes the majority of cost. Cost 
of treatment was similar across all age and risk groups.
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objeCtives: The aim of this study is to investigate the medical costs of COPD 
patients in South Korea. Methods: We enrolled 300 COPD patients who had been 
treated and followed up for more than one year in the three hospitals from 2012 
to 2013. The hospital electronic database was used to obtain medical costs and the 
medical records were reviewed by physicians (respiratory specialists) to assess clini-
cal characteristics. We calculated annual maintenance costs per-patient according 
to disease severity, except the costs which were related to COPD exacerbation. The 
costs of COPD exacerbation per-case was calculated and divided into severe-exac-
erbation (hospitalization and emergency visit) costs and non-severe-exacerbation 
(outpatient visit) costs. Results: The annual maintenance costs per-patient was 
KRW 351,599, KRW 401,068, KRW 573,010 and KRW 999,506 for mild, moderate, 
severe and very-severe according to GOLD criterion, respectively. In case of the 
COPD exacerbation, the costs per-case for each non-severe exacerbation and severe-
exacerbation was KRW 163,495 and KRW 2,765,086. ConClusions: The severity of 
disease and exacerbation of COPD have a substantial impact on the medical costs of 
COPD patients. Improvement of lung function and reduction of occurrence of COPD 
exacerbation will be beneficial for the reduction of the health care expenditures.
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objeCtives: Asthma is one of the mostly seen chronic illnesses in Turkey, yet there 
are limited studies on cost of asthma in our country. In addition they were based on 
a central database and weight of disease. The aim of this study was estimating the 
nationwide cost of managing asthma and examining its variability depending on 
asthma control level. Methods: The clinical pathway for asthma was determined 
from the literature. Part of the data was collected from the expert’s clinical view. To 
calculate the direct costs, the medical management of adult asthma was estimated 
using ‘cost-of-illness’ methodology for one year per patient. All costs were calcu-
lated according to payer perspective. The costs covered were pyhsician visits, hos-
pitalizations, diagnostic tests, medicine and comorbid disease. Results: According 
to recent studies, the percentage of controlled, partially controlled and uncontrolled 
patients were 22%, 50%, and %28 respectively in Turkey. The cost of asthma calcula-
tion was based on weighted percentage of control. The mean annual cost per patient 
with controlled asthma was € 558,41, partially controlled asthma was € 594,86 and 
uncontrolled asthma was € 1040,63. Hospitalizations, physician visits, diagnostic 
tests, comorbidity and medication costs were estimated to be 4%, 11%, 11%, 28%, 
46% for controlled patient, 10%, 11%, 10%, 43%, 26% for partially controlled patient 
and 48%, 6%, 6%, 25%, 15% for uncontrolled patient respectively. ConClusions: 
The cost of adult asthma in Turkey is very high and it significantly depends on 
disease control level. As expected, uncontrolled patient’s cost is higher than that 
of controlled patient. Nationwide health policies such as education of patients and 
physicians, selecting the right treatment and smoking cessation strategies that 
target the effective control of asthma will play an important role in the reduction 
of the economic burden of disease.
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objeCtives: COPD is one of the leading causes of morbidity and mortality world-
wide and has a major burden on Russian’s health care system. It’s lead to frequent 
use of health care resources. The main aim of this study was to describe the direct 
costs for management of COPD patients with differing degrees of disease sever-
ity. Methods: The methodology for cost of illness analysis was based on a previ-
ous Russian study (Avksenteva M. V. et al., 2010). One-year costs were identified by 
applying cost data to medical information obtained by medical statistical records 
from 2007. In this study were performed 2 variants of COPD costs. In 1st variant were 
used epidemiological data from 2007 and medical resources costs from 2014. In 2nd 
variant were used extrapolated epidemiological data and medical resources costs 
from 2014. Due to lack of actual data in this study was modeled situation – from 2007 
to 2012 the overall incidence of adult increased by 12.5%. Medical resources included 
hospital stays, outpatient visits and ambulance service. Results: The mean annual 
overall direct health care cost for 1st variant was estimated to be 54.6 billion rubles 
($1.6 billion), for 2nd variant was estimated to be 61.6 billion rubles ($1.8 billion). The 
son cohorts. After applying a 1: 1 matching, a total of 123,356 patients were matched 
from each cohort, with well-balanced baseline characteristics. COPD patients had 
higher health care utilization, including Medicare carrier (98.1% vs. 70.1%), Durable 
Medical Equipment (DME, 37.4% vs. 15.8%) and Home Health Agency (HHA, 17.2% 
vs. 4.6%) claims, outpatient visits (73.9% vs. 41.7%) and inpatient (32.5% vs. 6.8%), 
skilled nursing facility (SNF, 10.0% vs. 2.2%) and hospice admissions (1.2% vs. 0.6%) 
and prescription drug claims (53.4% vs. 49.8%), resulting in higher health care costs 
for Medicare carrier ($3,391 vs. $1,313), DME ($413 vs. $97), HHA ($923 vs. $228), 
outpatient ($10,110 vs. $3,514), inpatient ($5,983 vs. 1,045), SNF ($1,982 vs. $368), 
hospice ($304 vs. $143), pharmacy ($1,180 vs. $692) and total costs ($24,288 vs. $7,399) 
(p< 0.0001). ConClusions: COPD patients are associated with high economic bur-
den and health care utilization.
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objeCtives: Asthma is the most common chronic disease in childhood, reduces 
the quality of life of children and their families, and produces high social and 
health care costs. The aim of this study was to estimate the direct cost of pediat-
ric asthma in Turkey and to examine its variability depending on asthma control 
level. Methods: The clinical pathway for childhood asthma was designed by and 
based on the data from the available Turkish literature. Unavailable data was col-
lected by the expert’s clinical view. To calculate direct costs, the medical manage-
ment of childhood asthma estimated using ‘cost-of-illness’ methodology for one 
year per child. All costs were calculated from the health care payer perspective. The 
costs were covered hospitalizations, physician visits, diagnostic tests, medications 
and co morbid diseases. Results: According to the recent studies, the controlled 
patient was 60%, partial controlled patient was 25%, and uncontrolled patient was 
15% in Turkey. The cost of asthma calculation was based on weight of control. The 
mean annual cost per patient with controlled asthma is 542.97€ , partial controlled 
asthma 714.52€ and uncontrolled asthma 1047.86€ . Hospitalizations, physician vis-
its, diagnostic tests, co morbid diseases costs and medication costs estimated 4 %, 
21%, 7%, 27%, 40% of total costs for controlled patient, 27%, 16%, 5%, 21%, 31% of 
total costs for partial controlled patient and 50%, 11%, 4%, 14%, 21% for uncontrolled 
patient respectively. ConClusions: The direct cost of pediatric asthma in Turkey 
increases depending on disease control level along with different spectrum of item 
distributions. To increase the utility and effectiveness of health care system, the 
findings of this evaluation may guide to construct future policies.
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objeCtives: Pulmonary arterial hypertension (PAH) is a rare disease, for which only 
scarce health care cost data is available in Europe. The progressive nature of the 
disease often requires hospitalization, the costs of which are currently unknown 
in Belgium, mainly due to the low number of patients affected. The objective of 
this research was to assess the cost and length of stay (LOS) of a PAH-related hos-
pitalization likely related to disease worsening in Belgium. Methods: A retro-
spective database analysis was performed using the IMS hospital disease database 
from 2009 to 2011, covering 20% (2010/2011) to 34% (2009) of the hospital beds in 
Belgium. Data on adult patients, who were either hospitalized with a primary 
diagnosis of primary pulmonary hypertension (PH) (ICD-9-CM code 416.0) OR were 
receiving ≥ 1 medication indicated for PAH, was extracted. To ensure hospitaliza-
tions were likely related to disease worsening and not to planned procedures or 
routine visits, only unscheduled hospitalizations of at least 2 days were included 
in the analysis. Hospitalizations were excluded if primary co-diagnoses were sug-
gestive of a non-PAH-related reason for the admission. Total hospitalization costs, 
including hotel, drugs, procedure costs (extrapolated to 2013), and length of stay 
(LOS) were analyzed with descriptive statistics. Results: 35 hospitalizations were 
included into the study. Patients experiencing these admissions were mainly female 
(71.4%), which is in line with the known female-male ratio (2-1) for this rare dis-
ease. Mean (SD) hospitalization cost was € 20,229 (9,399), including € 4,396 (9,502) 
drug, € 8,499 (8,999) hotel, and € 7,334 (12,386) procedure costs. Average LOS was 
17.7±16.8 days. ConClusions: Long durations and high incurred costs for PAH-
related hospitalizations reveal the severe morbidity, health care, and patient burden 
of PAH in Belgium.
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objeCtives: Community-acquired pneumonia (CAP) represents a considerable bur-
den in Russia. We assessed cost of CAP in Russia to characterize disease burden in 
Russian adults of age 50 and older. Methods: We conducted a retrospective chart 
review in a central Russian region of Tver for samples of 900 patients treated in inpa-
tient and outpatient settings, and extrapolated data nationally. All patients were 50 
years of age and represented new cases of CAP. Data were collected on demograph-
ics, comorbidities, and employment. The cost was estimated from the public payer 
perspective, with a productivity loss in patients below retirement age. Results: 
Cost of treatment was similar across age-and-risk groups in hospital and in outpa-
tient settings. The cost of an outpatient episode was estimated far all risk groups at 
RR2176 ($69), ranging from RR1,939 ($61) to RR2537 (~$80) for age groups 50-64 and 
75-84 respectively; the cost of episode for low-risk patients was RR1737 ($55), and 
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culated. Methods: The costs including lab investigation charges, unit costs of 
treatment per bed, medication charges, food costs, transportation costs and loss of 
productivity were calculated per asthma episode. Data was analysed by Statistical 
Package for the Social Sciences (SPSS) version 18.0 using various descriptive and 
inferential statistical tests. Results: A median medical cost of acute exacerbation 
of asthma under Ministry of Health’s (MOH) perspective was USD 105.00 (RM338.47) 
per episode. Medication cost comprised the majority (52.38%) of the total medical 
costs. A median medical cost of acute exacerbation of asthma under patient’s per-
spective was USD 1.55 (RM4.99) per episode. ConClusions: Asthma exacerbation 
and length of stay in the hospital were proportional to the direct medical costs. In 
Malaysia, a substantial proportion of the direct medical cost of asthma treatment 
is heavily subsidised for the locals.
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objeCtives: Acute exacerbation of chronic obstructive pulmonary disease 
(AECOPD) appears to be the main reason of hospitalization in COPD patients. Since 
substantial economic burden of COPD have not been previously studied in Malaysia, 
this study aimed at estimating and identifying different costs and related burden 
of illness in patients receiving treatment of AECOPD in a tertiary care hospital in 
Malaysia. Methods: A prospective follow-up study was performed in Department 
of Accident and Emergency and Respiratory Medicine of the hospital. Data were 
derived on the basis of per exacerbation episode. Relationship between direct medi-
cal costs and disease severity was analyzed using various descriptive and inferential 
statistical approaches. Results: Median actual direct medical costs and out-of-
pocket costs were RM 457.68 (US$ 141.97) and RM 28.25 (US$ 8.76) per exacerbation 
respectively. Drug cost (41%) was the leading cost driver, followed by unit cost of 
treatment per bed (33.6%) and lab investigation cost (25.4%). However, food cost 
(44.2%) represented the largest proportion in out-of-pocket costs. More than 90% of 
actual direct medical costs were supported by the Government of Malaysia in the 
patients studied. ConClusions: Impacts of AECOPD in health care resources are 
worthy of attention. Cost information from pharmacoeconomic studies is impor-
tant in decision making for health care professionals and policy makers in order to 
improve health care outcome and minimize costs.
PRS39
PRoSPecTive STudy on The aveRage coST of TheRaPy foR bRonchial 
aSThMa PaTienTS in an indian TeRTiaRy caRe Teaching hoSPiTal
Nair S.V., Abdulsalim S., Yedavalli N.S., Shukla R., Mohan M.K.
Manipal University, Manipal, India
objeCtives: To conduct a study to determine the average cost of therapy for bron-
chial asthma patients in a tertiary care center. Methods: A prospective obser-
vational study was carried out on a 100 bronchial asthma patients after ethical 
clearance was obtained from an Independent Ethical Review (IEC) board. The patients 
selected for the study were in-patients admitted to the Medicine and Pulmonary 
wards for bronchial asthma related complaints with and without co-morbidities. 
The study assessed the average cost of therapy which was obtained from patient 
records. Statistical analysis was performed using SPSS version 20. Results: The 
mean age of the study population (N= 100) was 53.30±14.59. Females constituted 61% 
of the study population. The job profiles of the majority of study population were 
house wives (53%) and agriculturist (15%). The average cost of therapy among 100 
patients was found to range from $1.81 to $598. The impact on the length of stay on 
cost of therapy per day was classified into ≤ 5, 6-10, 11-21 days and cost was found to 
be $9.21 ± 5.57, $12.12 ±9.65 and $15.56±10.36 respectively. Impact of co-morbidities 
(35%) and without co-morbidities on cost of therapy per day was found to be $13.03 
± 10.63 and $8.54 ± 6.77 respectively. ConClusions: Asthma creates a substantial 
financial burden on the society and results in compromise on diagnosis and treat-
ment mainly in a developing country like India. There was a substantial increase in 
the cost of therapy as the duration of hospital stay increased and also in the case 
of patients with co-morbidities. Pharmacoeconomic analysis is needed to develop 
strategies to reduce the cost of therapy and thereby achieve greater medication 
adherence and improved quality of life in asthma patients.
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objeCtives: The objective of this cost study was to measure the resource utili-
sation and the direct costs associated with health care management of patients 
with chronic obstructive pulmonary disease (COPD) in Slovakia and to provide a 
basis for cost-effectiveness evaluations. Methods: The cross-sectional survey was 
performed to obtain the information on the management of patients with COPD 
and to estimate the direct costs of the disease management. The survey included 
4 experts experienced in COPD treatment. The studied population were cohorts of 
COPD patients evaluated separately according to the stage of the disease (mild, mod-
erate, severe and very severe). The patients were treated with standard therapy, the 
cost were set for one average patient per 3 months of treatment. The cost data were 
assessed and actualized due the 1st July 2014. All types of health care used in COPD 
management were evaluated (hospitalization, outpatient visits, diagnostics, labo-
ratory tests and the management of symptoms, use of bronchodilators). Moderate 
structure of direct costs in Russia was as follows – 77% for hospital stays, 21% for out-
patient visits, 2% for ambulance service. COPD exacerbations contributed the major 
portion of cost and also correlated with disease severity. ConClusions: COPD 
associated with significant economic burden on Russian’s health care system. There 
is a striking direct relationship between the cost of care and severity of the disease 
with hospitalization leading to disease exacerbation being a major portion of cost.
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objeCtives: Atopic dermatitis is a global public health concern considering its 
growing prevalence and mounting socioeconomic burden. However, Few studies 
has assessed the economic impact of atopic dermatitis in Korea. To conduct a cost 
analysis of atopic dermatitis and evaluate the economic impact of the disease on 
individual annual disease burden, quality of life, and change in medical expenses 
in regards to change in health related quality of life. Methods: This prospective 
cost analysis of atopic dermatitis by reviewing the housekeeping account books 
of 32 patients was conducted and evaluated the economic impact of the disease 
by analyzing the completed questionnaires. To handle the potential uncertainties, 
we compared the results with the data released by the Health Insurance Review & 
Assessment Board on medical costs claimed by the health care facilities. Results: 
In regards to the cost of illness, direct cost of atopic dermatitis per patient during 
the 3 month study period was 541,280 KRW and expenditure on other atopic derma-
titis related products was 120,313 KRW. Extrapolated annual direct cost (including 
expenditures on other atopic dermatitis related product) per patient was 2,646,372 
KRW. Estimated annual indirect cost was 1,507,068 KRW. Annual cost of illness of 
atopic dermatitis, computed by adding up direct and indirect costs, was estimated 
to be 4,153,440 KRW. ConClusions: The annual total social cost on a national level 
was estimated at 5.8000 trillion KRW.
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objeCtives: There are three main funding sources of health system In Mongolia 
which are state budget, health insurance and out of pocket payment. Health insur-
ance funded health care service based on 115 DRG and total financing to health care 
organizations were 87.1 billion MNT in 2011. Health insurance rates 240000 MNT 
secondary and thirtary level of hospital by the same tariff. Aim of the study is to 
calculate 10 DRG costs which were spent 25 percent of the health insurance fund 
in 2012. Methods: We used both top down and bottom-up cost allocation method. 
Secondary data were used.  Results: Respiratory diseases finance is 9 percent 
higher than the real cost. Other 9 diagnostic groups finance were less than actual 
cost by 8-62%. That the total funding based on the number of cases nationwide, 
12,032,906,381 MNT funding was insufficient. ConClusions: Health insurance 
base tariff have to change based on the study while base rates should be different 
at secondary and thirtary level of health care organization.
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objeCtives: To assess the direct and indirect medical costs incurred in 
the treatment of tuberculosis (TB) in patients attending public hospitals in 
Pakistan. Methods: A descriptive cross-sectional study was conducted in patients 
attending Accident and Emergency and TB wards of the hospitals in Pakistan by con-
venient-sampling technique. The direct and indirect medical costs were determined 
by various parameters like consultation fees, cost of medicines, travelling costs 
and laboratory test expenses etc. All obtained data were analyzed using descrip-
tive and inferential statistics. Results: The mean annual direct medical cost for 
a TB patient was around Rs. 17317.56 (US$ 176.26) and indirect medical cost was 
Rs. 12918.50 (US$ 131.48). It was also observed that ccomparatively higher direct 
and indirect medical costs per patient (p < 0.001) were associated with large and 
urban hospitals. Besides, association of indirect medical costs with gender and age 
were the persuasive predictors of the study. ConClusions: Severity of the disease, 
distance to the hospital and length of stay in the hospital were proportional to the 
direct and indirect medical costs. In Pakistan, a significant proportion of the direct 
medical cost for TB treatment is subsidized for the public.
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objeCtives: The cost of acute exacerbations of asthma had not been well stud-
ied in literature. The aim of this study was to identify and quantify the (average) 
cost of moderate and severe exacerbations of asthma in patients attending ter-
tiary-care setup in Malaysia. The related burden of exacerbations was also cal-
